Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The main reasons for reduced number of clinical trial applications in Bosnia and Herzegovina (BH)

  • At: 2016 FIP Congress in Buenos Aires (Argentina)
  • Type: Poster
  • By: INJAC, Dijana (Agency for medicinal products and medical devices of Bosnia and Herzegovina, Department for clinical trials, Laktasi, Bosnia and Herzegovina)
  • Co-author(s): Dijana Injac:Department for clinical trials,Agency for medicinal products and medical devices of Bosnia and Herzegovina,Banja Luka,Bosnia and Herzegovina|Andjelka Stupar:Department for clinical trials,Agency for medicinal products and medical devices of Bosnia and Herzegovina,Banja Luka,Bosnia and Herzegovina|Aleksandar Zolak:Cabinet of the Agency Director,Agency for medicinal products and medical devices of Bosnia and Herzegovina,Banja Luka,Bosnia and Herzegovina
  • Abstract:

    Regulatory Agency issues approvals for clinical trials. The trend of reduction was noted by the Regulatory Agency through monitoring the annual clinical trial applications.

    The survey research carried out by means of an electronic questionnaire included thirteen registered CROs. Twelve possible reasons for the reduced number of clinical trials were

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses